**Core Concept**
Maraviroc is an HIV-1 entry inhibitor that targets the CCR5 co-receptor on the surface of immune cells, specifically CD4+ T cells. This interaction with the CCR5 receptor prevents the fusion of the viral envelope with the host cell membrane, thereby inhibiting the entry of HIV-1 into the host cell.

**Why the Correct Answer is Right**
Maraviroc specifically binds to the CCR5 co-receptor on the surface of CD4+ T cells, preventing the interaction between the viral envelope gp120 and the CCR5 co-receptor. This binding blocks the fusion of the viral envelope with the host cell membrane, effectively inhibiting the entry of HIV-1 into the host cell. The CCR5 co-receptor is a key player in the HIV-1 entry process, and maraviroc's action on this receptor makes it an essential component in the treatment of HIV-1 infection.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because maraviroc does not act as a reverse transcriptase inhibitor, which is a different class of antiretroviral drugs that targets the viral reverse transcriptase enzyme.

**Option B:** This option is incorrect because maraviroc does not act as a protease inhibitor, which is another class of antiretroviral drugs that targets the viral protease enzyme.

**Option C:** This option is incorrect because maraviroc does not act as an integrase inhibitor, which is a class of antiretroviral drugs that targets the viral integrase enzyme.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that maraviroc is specifically indicated for use in treatment-experienced patients with HIV-1 infection who have evidence of R5-tropic virus, as it has been shown to be effective in reducing viral load in this population.

**Correct Answer:** C.